INFORMATION DISCLOSURE (17508.577) IN AN APPLICATION (Use several sheets if necessary) Sheet 1 OF 2 September 26, 2001 1635, 116	<u> </u>						
(Use several sheets if necessary) Applicant Kandimalla Filing Date Group Art Unit	\overline{C}						
(Use several sheets if necessary) Filing Date Group Art Unit	<u>m</u>						
Shoot 1 OF 2 TRAVELEY Filing Date Group Art Unit	ENTER						
Shoot 1 OE 0 1 1 1 1 1 1 1 1 1	==						
Sheet 1 OF 2 September 26, 2001 (635 1632	1600						
U.S. Patent Documents	28 -						
EXAMINER DOCUMENT DATE NAME CLASS SUBCLASS FILING D							
NUMBER	HIATE						
Foreign Patent Documents EXAMINER DOCUMENT DATE COUNTRY CLASS SUBCLASS TRANSLA	TION						
INITIAL NUMBER DATE COUNTRY CLASS SUBCLASS YES	NO						
Other Documents (Including Author, Title, Date Pertinent Pages	, Etc.)						
C1. Khorana et al. (1972) "Studies on Polynucleotides," J. Molec. Biol. 72:209 Reese (1978) "The Chemical Synthesis of Oligo- and Poly-Nucleotides By The Phosporotriester Approach,"							
C2. Tetrahedron 34:3143-3179 Beaucage et al. (1981) "Deoxynucleoside Phosphoramidites – A New Class of Key Intermediates for							
Deoxypolynucleotide Synthesis," Tetrahedron Lett. 22:1859-1862							
Sequence With A Phosphorothioate Group At The Cleavage Site," Biochemistry 23:3443	Connolly et al. (1984) "Synthesis and Characterization of an Octanucleotide Containing the EcoRI Recognition						
C5. Agrawal et al. (1987) "Oligodeoxynucleotise Methylphosphonates: Synthesis and Enzymic Degradation," Tetrahedron Lett. 28(31):3539-3542							
Jager et al. (1988) Oligonucleotide N-Alkylphosphoroamidates: Synthesis and Binding to Polynucleotides,"							
Agrawal et al. (1988) "Oligodeoxynucleoside Phosphoroamidates and Phosporothioates As Inhibitors of Human							
Immunodeficiency Virus, <i>Proc. Natl. Acad. Sci. USA</i> 85:7079-7083 C8. (Zon et al. (1991) "Phosphorothioate Oligonculeotides" <i>Oligonucleotides and Analogues: A Practical Approach</i>							
Kuramoto et al. (1992) "Oligopucleotide Sequences Required For Natural Killer Cell Activation." Jpn. J. Cance	er Res.						
C9. Rutanioto et al. (1992) Cingoritate Sequences responsed to trialitate Nation Set Activation, Spir. 9. Sandar 1888 83:1128-1131 Crooke (1993) "An Overview of Progress in Antisense Therapeutics," 8 Antisense & Nucl. Acid Drug Dev. 115-122							
CRC Press, Boca Raton, Florida							
C11. Zon (1993) "Protocols for Oliognucleotides and Analogs," Methods in Molecular Biology Vol. 20, pp. 165-189 C12. Pisetsky et al. (1994) "Stimulation of Murine Lymphocyte Proliferation By A Phosphorothioate Oligonucleotide With							
Yamamoto et al. (1994) "Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence of	if						
C13. AACGTT to Murine Spenocytes Enhances Interferon Production and Natural Killer Activity," 38 Microbiol. Immunol.							
C14. Agrawal et al. (1995) "Modified Oligonucleotides as Therapeutic and Diagnostic Agents," Curr.Opin.Biotechnol. 6:12-							
C15. Krieg et al. (1995) "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation," Nature 371:546-549							
C16. Klinman et al. (1996) "CpG Motifs Present In Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Interleukin 12, and Interleuron γ," 93 <i>Proc. Natl. Acad. Sci. USA</i> 2879							
Liang et al. (1996) "Activation of Human B Cells By Phosphorothioate Oligodeoxynucleotides," J. Clin. Invest. 98:1119-1129							
C18. Zhao et al. (1996) "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation," Bi	ochem.						
C19 Chu et al. (1997) "CpG Oligodeoxynucleotides Act As Adjuvants That Switch On T Helper 1 (Th1) Immunity," 186 J.							
DATE CONSIDERED 9-3-03							
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through of	ritation						
if not conformance and not considered. Include copy with next communication to applicant.							
BOSTON 1299404V1 Comby Le							
may de							

Subt. Form	PTO-1449	Docket Number	
İ		HV7-470CD	Application Number
INI	FORMATION DISCLOSURE P	E 47508.577)	09/965,116
	IN AN APPLICATION (C)	Applic	<u> </u>
(l	Use several sheets if necessary DEC 1	7 2001 E Kandir	
Sheet	2 OF 2 37.	Filing Date	Group Art Unit
	2 (8)		1635 1 832 B
JC20	O. Dunford et al. (1997) "Antisense 97: Targeting to Abstract, pp. 40	he Molecular Basis of Disease" (Nati	ure Biotechnology) Conference
C2	Mediated Shock," 27 Eur. J. Immunol, 1671	Pathogens Via DNA Motifs: Induction	of Tumor Necrosis Factor-α-
C22	Oligonucleotides in Mice." 7 Antisense Nucleic A		
CŚ	3. MCCiuskie et al. (1998) "Cutting Edge: CpG DN/ Responses Against Hepatitis B Surface Antigen	A Is A Potent Enhancer of Systemic	
C24	Influenza Virus." Vaccine 16:1216-1224	minute Emiliancer for Systemic and M	lucosal Immunization With
	Sparwasser et al. (1998) "Bacterial DNA and Impact Activation of Murine Dendritic Cells," 28 Eur. J.		
C26	 Vilokunaga et al. (1999) "How RCG Led to the Die 	contont of Immunication the matter	52 Jap. J. Infect. Dis. 1
C27	Modulates Its Immunostimulatory Activity " Ricor	is in ope containing Phosphorothic	ate Oligodeoxynucleotide
C28	1. Today 72	s It As Simple As Complementary Ba	se Recognition," 6 Mol. Med.
C29	Zhao et al. (2000) "Immunostimulatory Activity of Modulated by Modification of a Single Deoxynucl	CpG Containing Phosphorothicate (leoside," Biocra, & Med. Chem. Lett.	Oligodeoxynucleotide is
		gramos. Onom. Lau.	10.1031-1034
			
			
XAMINER	() 1.10 = 1	DATE CONSIDERED	
/	fret I Share for a	9-2-17	
XAMINER!	Initial if citation is considered, whether or not citation	n is in conformance with MDED 5 co.	2: Droyal in a the control of the
not conformar	nce and not considered include copy with next comm	nunication to applicant.	. Draw Line through citation
XAMINER / XAMINER/ not conformar	Initial if citation is considered, whether or not citation nce and not considered include copy with next communication.	9-3-03	9: Draw Line through citatic

BOSTON 1299404v1

Smily the

6/30/04

Subt. Form P		WICODN.	PIP		ket Number Z-479CP	Ap (oplication Nu 09/965.1	umber 146_CF
SUFF	PLEMENTAL DISCLOS			(475	508.577)		<i>5/000</i> , ,	J. Ck
	IN AN APPL	LICATION	FEB 0 1 2002	92 E		Applicant Indimalla		
aı	to soveral char	-1- # 30000F	4.	e.		anriana		FEB 0
	se several sheel	IS II HECESSA	RADEMARY	fe ^v Filir	ing Date	(Group Art U	Joit CIVIER
Sheet	1	OF	1	Septemb	per 26, 200	л	1632	
			U.S. Pate	ent Docume	ente			
XAMINER	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILIN	G DATE
With the same	INDIAPPLI	<u> </u>				0000	IF APPR	ROPRIATE
			Foreign Pa	tent Docum	- cata			
XAMINER	DOCUMENT	DATE		OUNTRY	CLASS	TOURCLASS	TRANS	SLATION
INITIAL	NUMBER WO 99/62923			PCT	CLASS	SUBCLASS	YES	NO
		<u> </u>		FOI	+			
		Oth	or Docume	nto (Includio	- Andhau Tid	· Data Boot		
			31 DOCUME.	ents (Including	Author, rice	e, Date Peru	nent Page	es, Etc.)
							=	
					=			
				/				
			/					
		—						
	7							
/								
CAMINER				DATE CONSI	IDERED			
	\mathcal{L}	. `		1	130/04			
(1 1	•		1/1	1.~0			1

BOSTON 1319148v1

SHEET	1	OF	1
		~ -	

Subt. Form PTC-1449

SUPPLEMENTAL INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Dücket Number

Application Number

EY6-005US2

09/965,116

Applicant

Filing Date

Kandimalla et al.

Group Art Unit

•

-1632 /635

9/26/01
U.S. PATENT DOCUMENTS

		U .,	O. 1 MILITA E	OCCINEIT	<i>-</i>		
EXAMINER INITIAL	IDENTIFIER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
			,-	_		.	
		-				1	IVED
						HEU	
						1	8 5005
	l 			-		001	20000
						-1	TER 1600/2900
						TECH CE	AICI
	<u> </u>	F001	TICAL DATEN	TOOCHME	ITC	100	

FOREIGN PATENT DOCUMENTS

IDENTIFIER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	NUMBER				[YES	NO
			-				
				 			
	IDENTIFIER			IDENTIFICATION TO THE PROPERTY OF THE PROPERTY	IDENTITION OF THE PROPERTY OF	DENTITIES SOUTHERN	DENTITIES SOCIETY

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	EXAMINER	IDENTIFIER	
Ju	INITIAL	C1	Agrawal et al., "Antisense Therapeutics", Curr. Opin. Chem. Biol., 2:519-528, 1998.
		C2	Chaix et al., "3'-3' Linkied Oligonucleotides: Synthesis and Stability Studies", Bioorganic & Medicinal Chemistry Letters, 6:827-832, 1996.
	. ,	C3	Klinman, Dennis M., "Therapeutic Applications of CpG-Containing Oligodeoxynucleotides", Antisense & Nucleic Acid Drug Development, 8:181-184, 1998.
		C4	Yu et al., "Accessible 5'-End of CpG-Containing Phosphorothioate Oligodeoxynucleotides is Essential for Immunostimulatory Activity", <i>Bioorganic & Medicinal Chemistry Letters</i> , 10: 2585-2588, 2000.
		C5	Kandimalla et al., "Effect of Chemical Modifications of Cytosine and Guanine in a CpG-Motif of Oligonucleotides: Structure-Immunostimulatory Activity Relationships", <i>Bioorganic & Medicinal Chemistry</i> , 9:807-813, 2001.
У	h	C6	International Search Report in connection with Patent Cooperation Treaty Application No. PCT/US01/30137.

fruit 1. 970 Food

9-2-03